The diagnosis and treatment of prostate cancer have undergone tremendous changes in recent years, with the emergence of new therapeutic options. The “1st Symposium on SBRT for Organ-Confined and Oligometastatic Prostate Cancer” aims to promote a dynamic and multidisciplinary exchange among radiation oncologists and medical physicists, with a particular focus on the potential and challenges of stereotactic body radiotherapy (SBRT). In recent years, the use of SBRT for the treatment of prostate cancer-both in its localized and (oligo)metastatic stages-has rapidly expanded, supported by growing scientific evidence demonstrating its efficacy, tolerability, and positive impact on quality of life. In this context, the symposium offers a unique opportunity to explore the technological innovations that have enabled the safe and precise delivery of ablative doses, thanks to advances in treatment planning, imaging, tracking systems, and motion management techniques. The event will also delve into the emerging role of adaptive and personalized strategies, the integration of SBRT with systemic therapies, and the biological and clinical implications of these combinations in light of the most recent evidence. Through interactive sessions, clinical case discussions, and round tables, the symposium aims to foster expert dialogue, with the goal of supporting a clinical practice increasingly driven by scientific evidence, patient-centered care, and long-term toxicity reduction. Finally, the event seeks to strengthen collaboration between institutions, promoting synergies in clinical and translational research, and paving the way for the continuous and shared evolution of radiation oncology in the treatment of prostate cancer.